Skip to main content
PMC home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1999 Aug 24;161(4):405–411.

Tuberculosis: 9. Treatment

E Hershfield 1
PMCID: PMC1230544  PMID: 10478167

Full Text

The Full Text of this article is available as a PDF (225.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Addington W. W. Patient compliance: the most serious remaining problem in the control of tuberculosis in the United States. Chest. 1979 Dec;76(6 Suppl):741–743. doi: 10.1378/chest.76.6_supplement.741. [DOI] [PubMed] [Google Scholar]
  2. Alangaden G. J., Lerner S. A. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin Infect Dis. 1997 Nov;25(5):1213–1221. doi: 10.1086/516116. [DOI] [PubMed] [Google Scholar]
  3. Borcherding S. M., Baciewicz A. M., Self T. H. Update on rifampin drug interactions. II. Arch Intern Med. 1992 Apr;152(4):711–716. [PubMed] [Google Scholar]
  4. Cambau E., Sougakoff W., Besson M., Truffot-Pernot C., Grosset J., Jarlier V. Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J Infect Dis. 1994 Aug;170(2):479–483. doi: 10.1093/infdis/170.2.479. [DOI] [PubMed] [Google Scholar]
  5. Carpenter C. C., Fischl M. A., Hammer S. M., Hirsch M. S., Jacobsen D. M., Katzenstein D. A., Montaner J. S., Richman D. D., Saag M. S., Schooley R. T. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA. 1997 Jun 25;277(24):1962–1969. [PubMed] [Google Scholar]
  6. D'Esopo N. D. Clinical trials in pulmonary tuberculosis. Am Rev Respir Dis. 1982 Mar;125(3 Pt 2):85–93. doi: 10.1164/arrd.1982.125.3P2.85. [DOI] [PubMed] [Google Scholar]
  7. FOX W. The problem of self-administration of drugs; with particular reference to pulmonary tuberculosis. Tubercle. 1958 Oct;39(5):269–274. doi: 10.1016/s0041-3879(58)80088-4. [DOI] [PubMed] [Google Scholar]
  8. Girling D. J. Adverse reactions to rifampicin in antituberculosis regimens. J Antimicrob Chemother. 1977 Mar;3(2):115–132. doi: 10.1093/jac/3.2.115. [DOI] [PubMed] [Google Scholar]
  9. Hodges M. K., Israel E. Tracheobronchopathia osteochondroplastica presenting as right middle lobe collapse. Diagnosis by bronchoscopy and computerized tomography. Chest. 1988 Oct;94(4):842–844. doi: 10.1378/chest.94.4.842. [DOI] [PubMed] [Google Scholar]
  10. Jindani A., Aber V. R., Edwards E. A., Mitchison D. A. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis. 1980 Jun;121(6):939–949. doi: 10.1164/arrd.1980.121.6.939. [DOI] [PubMed] [Google Scholar]
  11. Kennedy N., Berger L., Curram J., Fox R., Gutmann J., Kisyombe G. M., Ngowi F. I., Ramsay A. R., Saruni A. O., Sam N. Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clin Infect Dis. 1996 May;22(5):827–833. doi: 10.1093/clinids/22.5.827. [DOI] [PubMed] [Google Scholar]
  12. Kennedy N., Fox R., Kisyombe G. M., Saruni A. O., Uiso L. O., Ramsay A. R., Ngowi F. I., Gillespie S. H. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am Rev Respir Dis. 1993 Dec;148(6 Pt 1):1547–1551. doi: 10.1164/ajrccm/148.6_Pt_1.1547. [DOI] [PubMed] [Google Scholar]
  13. Kopanoff D. E., Snider D. E., Jr, Caras G. J. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis. 1978 Jun;117(6):991–1001. doi: 10.1164/arrd.1978.117.6.991. [DOI] [PubMed] [Google Scholar]
  14. Mitchison D. A. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis. 1998 Jan;2(1):10–15. [PubMed] [Google Scholar]
  15. Mitchison D. A., Nunn A. J. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis. 1986 Mar;133(3):423–430. doi: 10.1164/arrd.1986.133.3.423. [DOI] [PubMed] [Google Scholar]
  16. Moulding T. S., Redeker A. G., Kanel G. C. Twenty isoniazid-associated deaths in one state. Am Rev Respir Dis. 1989 Sep;140(3):700–705. doi: 10.1164/ajrccm/140.3.700. [DOI] [PubMed] [Google Scholar]
  17. Perriëns J. H., St Louis M. E., Mukadi Y. B., Brown C., Prignot J., Pouthier F., Portaels F., Willame J. C., Mandala J. K., Kaboto M. Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med. 1995 Mar 23;332(12):779–784. doi: 10.1056/NEJM199503233321204. [DOI] [PubMed] [Google Scholar]
  18. Rothfield N. F., Bierer W. F., Garfield J. W. Isoniazid induction of antinuclear antibodies. A prospective study. Ann Intern Med. 1978 May;88(5):650–652. doi: 10.7326/0003-4819-88-5-650. [DOI] [PubMed] [Google Scholar]
  19. Smith C. K., Durack D. T. Isoniazid and reaction to cheese. Ann Intern Med. 1978 Apr;88(4):520–521. doi: 10.7326/0003-4819-88-4-520. [DOI] [PubMed] [Google Scholar]
  20. Snider D. E., Jr, Long M. W., Cross F. S., Farer L. S. Six-months isoniazid-rifampin therapy for pulmonary tuberculosis. Report of a United States Public Health Service Cooperative Trial. Am Rev Respir Dis. 1984 Apr;129(4):573–579. [PubMed] [Google Scholar]
  21. Snider D. E., Jr Pyridoxine supplementation during isoniazid therapy. Tubercle. 1980 Dec;61(4):191–196. doi: 10.1016/0041-3879(80)90038-0. [DOI] [PubMed] [Google Scholar]
  22. Snider D. E., Jr, Rogowski J., Zierski M., Bek E., Long M. W. Successful intermittent treatment of smear-positive pulmonary tuberculosis in six months: a cooperative study in Poland. Am Rev Respir Dis. 1982 Feb;125(2):265–267. doi: 10.1164/arrd.1982.125.2.265. [DOI] [PubMed] [Google Scholar]
  23. Sullivan E. A., Kreiswirth B. N., Palumbo L., Kapur V., Musser J. M., Ebrahimzadeh A., Frieden T. R. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet. 1995 May 6;345(8958):1148–1150. doi: 10.1016/s0140-6736(95)90980-x. [DOI] [PubMed] [Google Scholar]
  24. Trébucq A. Should ethambutol be recommended for routine treatment of tuberculosis in children? A review of the literature. Int J Tuberc Lung Dis. 1997 Feb;1(1):12–15. [PubMed] [Google Scholar]
  25. Varughese A., Brater D. C., Benet L. Z., Lee C. S. Ethambutol kinetics in patients with impaired renal function. Am Rev Respir Dis. 1986 Jul;134(1):34–38. doi: 10.1164/arrd.1986.134.1.34. [DOI] [PubMed] [Google Scholar]
  26. Vernon A., Burman W., Benator D., Khan A., Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet. 1999 May 29;353(9167):1843–1847. doi: 10.1016/s0140-6736(98)11467-8. [DOI] [PubMed] [Google Scholar]
  27. Yew W. W., Kwan S. Y., Ma W. K., Khin M. A., Chau P. Y. In-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis. J Antimicrob Chemother. 1990 Aug;26(2):227–236. doi: 10.1093/jac/26.2.227. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES